



### **Fera, an Emerging Pharmaceutical Company, Acquires a Portfolio of Ophthalmic Ointments**

NEW YORK—July 16, 2009/BusinessWire/— Fera Pharmaceuticals has acquired all rights, title and interest to seven prescription sterile anti-infective ophthalmic abbreviated new drug applications (ANDAs) marketed by Fougera, a division of Nycomed US Inc. The products include Bacitracin; Bacitracin Zinc and Polymyxin B Sulfate; Gentamicin Sulfate, Neomycin and Polymyxin B Sulfates and Bacitracin Zinc; Neomycin and Polymyxin B Sulfates and Dexamethasone; Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone Acetate as well Erythromycin Ophthalmic Ointments USP.

These seven products represent over 80% of the ophthalmic ointment market volume (source: IMS Health 2008).

Fera is pleased to be able to help meet the market demand for these important products and continue to provide physicians, pharmacies and patients more options when treating ocular infections.

Fera is currently accepting orders for Bacitracin and plans to ship in September. At launch, Fera will be distributing limited inventories of Fougera labeled Bacitracin while initiating technical transfers and obtaining required regulatory approvals for the rest of the line. It is anticipated Fera labeled product will be available early 2010.

#### About Fera Pharmaceuticals, LLC

Fera Pharmaceuticals is a privately held company. The company goal is to realize opportunities via acquisitions, in-licensing, developing and marketing abbreviated new drug applications (ANDAs), new drug applications (NDAs) and 505(b)(2) NDA products. Areas of interest include products that could benefit from lifecycle management with a special focus on niche markets. For more information visit [www.ferapharma.com](http://www.ferapharma.com).

Contact:

Frank J. DellaFera

516-277-1450  
[contact@ferapharma.com](mailto:contact@ferapharma.com)